Sarepta Therapeutics

Youtube Subscribe

Open: 126.68 Close: 126.36 Change: -0.32

The best way to get information about Sarepta Therapeutics Stock: Use an AI.

The game is changing. There is a new strategy to evaluate Sarepta Therapeutics fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Sarepta Therapeutics are: Sarepta, Therapeutics, rating, price, Buy, target, Sareptpt, …

Concept Map

Semantic Network

Stock Summary

Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. The company is also developing SRP-.

Today's Summary

Sarepta Therapeutics has a conensus rating of Strong Buy which is based on 15 buy ratings, 1 hold ratings and 0 sell ratings. Analysts estimate an earnings increase this quarter of $2.34 per share, a decrease next quarter of$0.00. Sarept is on an urgent mission: engineer precision genetic medicine.

Today's News

Sarepta Therapeutics has a conensus rating of Strong Buy which is based on 15 buy ratings, 1 hold ratings and 0 sell ratings. The average price target for Sareptpt Therapeuticss is $142.21.21. Sarepta Therapeutics, Inc. granted equity awards on November 30, 2023 that were previously approved by the Compensation Committee of its Board of Directors under Sareptas 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 13 individuals hired by SarePTas in November. Sarepta Therapeutics stock price is 126.46 USD today. The Sareptpt Therapeutic is a publicly traded company. Analysts estimate an earnings increase this quarter of $2.34 per share, a decrease next quarter of$0.00. Sarepta Therapeutics has a market cap of $11.83 Billion. This makes the company 1386th most valuable company by market cap. Sarepta Therapeutics (SRPT) is a Strong Buy with an average price target of $138.86, representing a 15.7% upside. Bank of America Securities maintained a Buy rating on Sareptpt with a price target $164.00. Sarepta Therapeutics announces inducement grants under nasdaq listing rule 5635(c)(4) About Sarept is on an urgent mission: engineer precision genetic medicine.

Stock Profile

"Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; and AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program that is under Phase 1/2a clinical trial; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Selecta Biosciences; Hansa Biopharma; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts."

Keywords

Are looking for the most relevant information about Sarepta Therapeutics? Investor spend a lot of time searching for information to make investment decisions in Sarepta Therapeutics. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Sarepta Therapeutics are: Sarepta, Therapeutics, rating, price, Buy, target, Sareptpt, and the most common words in the summary are: sarepta, therapeutic, stock, price, best, year, srpt, . One of the sentences in the summary was: Sarepta Therapeutics has a conensus rating of Strong Buy which is based on 15 buy ratings, 1 hold ratings and 0 sell ratings. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #sarepta #therapeutic #stock #price #best #year #srpt.

Read more →

Youtube Subscribe

---